astx660
Small moleculeexperimental
Clinical trial activity
11 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02503423)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Endometrioid · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Early Phase 1
- Carcinosarcoma · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Early Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Early Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Inhibitor of apoptosis protein 3INHIBITOR
XIAP inhibitor
- cIAP1/cIAP2INHIBITOR
cIAP1/cIAP2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- astx660
- astx660
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06393751 | Phase 1/Phase 2 (Phase 2) | May 2, 2025 | National Cancer Institute (NCI), NRG Oncology |
| NCT06590558 | Phase 1 | Nov 8, 2024 | National Cancer Institute (NCI), Ohio State University |
| NCT05912075 | Phase 1 | Jul 1, 2023 | Institut Gustave Roussy |
| NCT05403450 | Phase 1/Phase 2 (Phase 2) | Jun 23, 2022 | Astex Pharmaceuticals, Inc. |
| NCT05245682 | Early Phase 1 (Phase 1) | Feb 17, 2022 | Astex Pharmaceuticals, Inc., Emory University |
| NCT05082259 | Phase 1 | Dec 1, 2021 | Astex Pharmaceuticals, Inc., Cancer Research UK, Merck, Royal Marsden Hospital NHS Trust, University of London |
| NCT04479800 | Phase 1 | Jul 20, 2020 | Astex Pharmaceuticals, Inc. |
| NCT04411030 | Phase 1 | May 20, 2020 | Astex Pharmaceuticals, Inc. |
| NCT04362007 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Otsuka |
| NCT04155580 | Phase 1 | Jan 31, 2020 | Astex Pharmaceuticals, Inc. |
| NCT02503423 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | Astex Pharmaceuticals, Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astex Pharmaceuticals, Inc. | For profit | 7 | 5 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 2024 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Otsuka | For profit | 1 | 1 | 1 | 2020 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2021 |
11 organizations
Page 1 / 1